Calliditas Therapeutics: FDA approval of TARPEYO®
-
Calliditas Therapeutics announces full FDA approval of TARPEYO
, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function -
Calliditas: Interview with CEO Renée Aguiar-Lucander
"Redeye interviews Callidias CEO Renée Aguiar-Lucander, after securing a full FDA approval for Tarpeyo."
-
Everest Medicines Announces New Drug Application Acceptance of Nefecon
in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patien"SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon
has been accepted for review by the Taiwan Food and Drug Administration (TFDA) for the treatment of primary immunoglobulin A nephropathy (IgAN) in adult patients. Nefecon was the first ever treatment for IgAN approved in U.S., European Union and mainland China. Everest expects approval of Nefecon in Taiwan in 2024."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind